# Maat Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maat-pharma

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.maatpharma.com
- Total disclosed funding: $8.9M
- Latest round: Series B (Jan 15, 2021)
- Investors on record: 3

## About

Maat Pharma SA is a biotechnology firm specializing in microbiome-based therapies that enhance cancer treatment outcomes, aiming to improve patient health through innovative solutions.Founded in 2013 and headquartered in Lyon, France, Maat Pharma SA develops therapies focused on the microbiome to support cancer treatment. The company has successfully completed 8 deals, with its most recent funding round occurring on January 15, 2021, where it raised EUR 7.35 mn in Series B funding led by Bpifrance, alongside investors Celeste Management and Skyviews Life Science. The company's CEO and founder, Herve Affagard, has a background in biotechnology and entrepreneurship.Maat Pharma specializes in developing innovative microbiome-based therapies aimed at enhancing cancer treatment. Their core product offerings include specialized treatments designed to restore microbiome function, thereby improving patient outcomes in oncology. Notable products include Xervyteg®, MaaT033, MaaT034, and MaaT03X, which target various cancer indications. These therapies are primarily positioned to serve healthcare professionals and oncologists, working within a framework that supports patients undergoing cancer treatments. The company's products are marketed in several geographical regions, including Europe and North America, focusing on healthcare institutions and specialized clinics that cater to oncology patients.In 2022, Maat Pharma generated revenue of EUR 1,506,932.40, with an EBITDA of EUR 14,738,431.40. The company generates revenue through direct partnerships with healthcare institutions, where its microbiome therapies are integrated into treatment regimens for cancer patients. Their business model involves B2B transactions, where healthcare providers order treatments for their patients, and potential subscription agreements for ongoing access to updated products and therapies. Flagship products such as Xervyteg® may be offered under specific pricing structures tailored to institutional buyers, reflecting the therapeutic value provided to patients.Maat Pharma aims to leverage the EUR 7.35 mn raised in its Series B funding round to support the development of new microbiome-based therapies. The company is actively designing new products targeted at improving outcomes in oncology and plans to expand its market reach into additional regions, particularly focusing on Europe and North America by 2023. This expansion will enhance their service offerings to healthcare professionals and oncologists in those markets.

## Funding rounds

- Series B, Jan 15, 2021, $8.9M — Bpifrance, Celeste Management, Skyviews Life Science

## Investors

- Bpifrance — Series B
- Celeste Management — Series B
- Skyviews Life Science (https://capitalatlas.ai/funds/skyviews-life-science) — Series B